


USSN 10/762,907  
 37 C.F.R. § 1.111 Response  
 Page 2

Attorney Docket No. CT2739NP

### Amendments to the Claims

1. (original) A compound of the formula



wherein the wavy bond (~~~~) represents the racemate, the (R)-enantiomer or the (S)-enantiomer;  
 $R^1$ ,  $R^2$ ,  $R^3$ , and  $R^4$  each are independently hydrogen or  $-P(O)OR^5OR^6$ ;  
 $R^5$  and  $R^6$  each are independently hydrogen or  $C_{1-4}$  alkyl;  
 $X$  is a covalent bond or  $-CR^5R^6O-$ ;  
 or a nontoxic pharmaceutically acceptable salt or solvate thereof.

2. (original) The compound of claim 1 which is 3-(S)-(5-Chloro-2-methoxy-phenyl)-3-fluoro-6-trifluoromethyl-1-(3-(R), 4-(S), 5-(S)-trihydroxy-6-(R)-hydroxymethyl-tetrahydro-pyran-2-ylloxymethyl)-1,3-dihydro-indol-2-one or a pharmaceutically acceptable salt or solvate thereof.
3. (original) The compound of claim 1 which is 3-(S)-(5-Chloro-2-methoxy-phenyl)-3-fluoro-6-trifluoromethyl-1-(3-(R), 4-(S), 5-(S)-trihydroxy-6-(R)-hydroxymethyl-tetrahydro-pyran-2-(R)-yl)-1,3-dihydro-indol-2-one or a pharmaceutically acceptable salt or solvate thereof.
4. (original) The compound of claim 1 which is phosphoric acid mono-{2-(R)-[3-(S)-(5-chloro-2-methoxy-phenyl)-3-fluoro-2-oxo-6-trifluoromethyl-2,3-dihydro-indol-1-yl]-4-(S), 5-(S)-dihydroxy-6-(R)-hydroxymethyl-tetrahydro-pyran-3-(R)-yl} ester or a pharmaceutically acceptable salt or solvate thereof.
5. (currently amended) A pharmaceutical composition for the treatment of disorders responsive to openers of the large conductance calcium-activated potassium channels, the disorders consisting of cerebral ischemia and stroke with the composition comprising a therapeutically effective amount of

USSN 10/762,907  
37 C.F.R. § 1.111 Response  
Page 3

Attorney Docket No. CT2739NP

a compound as defined in claim 1 in association with a pharmaceutically acceptable carrier or diluent.

6. (currently amended) A method for the treatment of disorders responsive to opening of the large conductance calcium-activated potassium channels in a mammal in need thereof, the disorders consisting of cerebral ischemia and stroke and the method which comprises administering to said mammal a therapeutically effective amount of a compound as defined in claim 1.

7. (cancelled)

8. (currently amended) The method of claim 7-6 wherein the disorder is stroke.

9. (currently amended) The method of claim 7-6 wherein the disorder is cerebral ischemia ~~traumatic brain injury~~.